This report comprises a summary of IOG’s special Executive Workshop on Biotechnology, which was held under the patronage of Dr. Arthur Carty, National Science Advisor to the Prime Minister, and in collaboration with the Canadian Biotechnology Secretariat on May 25-26, 2004. The fourth event of IOG’s Biotechnology and Governance Program, the workshop was attended by approximately 50 people, including senior representatives from federal departments and agencies, industry, civil society organizations, provinces and academia. The workshop gave participants the opportunity to identify… Read more
This paper offers a short comparison of the CropLife Plant Biotechnology Code of Practice to the Queensland model and to the BIOTECanada Statement of Ethical Principles. It examines comparative strengths and weaknesses of the CropLife Code, and gives special consideration to CropLife Code’s compliance policy. Investigating this aspect of CropLife’s code facilitates a clearer understanding of the pros and cons of the approaches taken to develop and implement this code of practice and helps to identify implications for a proposed… Read more
There has been considerable interest in the Queensland Code for Biotechnology since its implementation in June 2001. In Canada, the Queensland Code has been considered a possible model for a Canadian Code for Biotechnology. To examine the development and effectiveness of this model, interviews were conducted with a number of stakeholders in Queensland, including representatives of industry, government and academic research. This report presents the results of these interviews and reports on the impact of the Code on biotechnology in… Read more
Prepared by the IOG for the Office of Biotechnology and Science at Health Canada, this paper investigates the benefits of a code for biotechnology in Canada and a possible model for such a code. It examines the rationale for a code, explores the merits and drawbacks of three model codes, and conducts a preliminary preference analysis based on stakeholder interviews. The paper concludes that the development of a code is worth pursuing, but that more consultation and research is required.
This paper explores what biotechnology information requirements legislators might have to support informed decision-making. It considers existing biotechnology education programs, including the National Judicial Institute and Genome B.C., and offers basic communication approaches to help provide legislators with effective decision-making tools.
This paper, prepared for the Canadian Biotechnology Secretariat, is a comparison of approaches taken by seven jurisdictions to two policy demands of biotechnology: cross-governmental coordination and strategy development. The jurisdictions examined include the European Union, the United Kingdom, the United States, Japan and Australia, as well as Quebec and Ontario.
This paper summarizes Forum III, the third event of IOG’s Biotechnology and Governance Program. The session brought together 60 decision-makers from both inside and outside government to examine biotechnology’s relevance to Canada’s foreign and international development policy.
This paper summarizes Forum I, the first event in IOG’s Biotechnology and Governance Program. Attended by some 50 senior managers in the federal government, as well as representatives of academe, civil society, media and industry, the session focused on the regulation and use of patents in the context of both higher life forms and the health care system.
Originally published in Nature Biotechnology, this paper has now been anthologized in a book by Michael Ruse and David Castle entitled Genetically Modified Foods, New York: Prometheus Books. It examines the ethical debate surrounding modern biotechnology from the process vs. product perspective, arguing that fully understanding these two viewpoints is crucial to moving the debate ahead.
Originally prepared for the Interdepartmental Working Group on Ethics and Public Confidence in Biotechnology, this paper argues that governments should consider ethical issues not only at the regulatory stage of biotech products, but during the entire product life cycle. The article develops a framework to identify the life cycle stage at which various ethical issues could be addressed and the sectors that could have a role in addressing these issues. The report will be published in a special 2005 ethics… Read more